Knight Therapeutics (FRA:04K) Long-Term Debt: €25.7 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:04K Knight Therapeutics Inc FRA:04K
73 GF Score
Price €6.00
GF Value €5.29
! 6 Warning Signs
View Full Analysis

What is Knight Therapeutics Long-Term Debt?

Knight Therapeutics FRA:04K 73 Long-Term Debt is €25.7 Mil as of Mar. 2026. GuruFocus rates FRA:04K with a GF Score™ of 73/100 and a GF Value™ of €5.29. The stock has 6 warning signs investors should review.

Knight Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2026 was €25.7 Mil.

Knight Therapeutics's quarterly Long-Term Debt declined from Sep. 2025 (€48.5 Mil) to Dec. 2025 (€31.7 Mil) and declined from Dec. 2025 (€31.7 Mil) to Mar. 2026 (€25.7 Mil).

Knight Therapeutics's annual Long-Term Debt declined from Dec. 2023 (€30.1 Mil) to Dec. 2024 (€17.4 Mil) but then increased from Dec. 2024 (€17.4 Mil) to Dec. 2025 (€31.7 Mil).

Knight Therapeutics  (FRA:04K) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Knight Therapeutics Long-Term Debt Related Terms

Knight Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Knight Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Knight Therapeutics Long-Term Debt Chart

Knight Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.41 36.41 30.09 17.36 31.67

Knight Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.97 50.01 48.49 31.67 25.68
FRA:04K
73GF Score
Knight Therapeutics Inc FRA:04K
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €25.7 Mil mean?
Knight Therapeutics (FRA:04K) has a Long-Term Debt of €25.7 Mil as of Mar. 2026.
Is Knight Therapeutics' Long-Term Debt too high?
Knight Therapeutics' current Long-Term Debt is €25.7 Mil. Overall, Knight Therapeutics has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' Long-Term Debt compare to ZTS and UTHR?
Knight Therapeutics' Long-Term Debt of €25.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Knight Therapeutics's current Long-Term Debt is €25.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Knight Therapeutics (FRA:04K) has a current Long-Term Debt of €25.7 Mil. The stock's GF Value™ is €5.29, compared to a current price of €6.00 — trading 13.4% above its estimated fair value. The current Long-Term Debt is €25.7 Mil. Knight Therapeutics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Knight Therapeutics (FRA:04K), the current Long-Term Debt is €25.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Knight Therapeutics (FRA:04K) Overvalued in 2026?

Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued. The current stock price of €6.00 is trading 13.4% above its estimated GF Value™ of €5.29.

Key valuation signals for FRA:04K:

  • Long-Term Debt: €25.7 Mil
  • GF Value™: €5.29 vs. price of €6.00 (13.4% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the FRA:04K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Knight Therapeutics Business Description

Other Exchanges KHTRF:USAGUD:Canada
Address 100 Alexis Nihon Boulevard, Suite 600, Saint-Laurent, QC, CAN, H4M 2P2
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
73GF Score

Get the complete analysis for FRA:04K

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.00
Price
€5.29
GF Value